Associations between vitamin D status and diabetic complications in Chinese population with type 2 diabetes mellitus: a cross-sectional study

CURRENT STATUS: Posted

Ying Xiao, Ling Wei, Xiaofen Xiong, Ming Yang, Lin Sun

Ying Xiao
Second Xiangya Hospital

Ling Wei
Second Xiangya Hospital

Xiaofen Xiong
Second Xiangya Hospital

Ming Yang
Second Xiangya Hospital

Lin Sun
Second Xiangya Hospital

sunlin@csu.edu.cn Corresponding Author
ORCID: https://orcid.org/0000-0002-4544-0822

10.21203/rs.3.rs-27652/v1

Subject Areas
Neurobiology of Disease Cardiac & Cardiovascular Systems

Keywords

vitamin D, diabetic retinopathy, diabetic kidney disease, diabetic foot ulcers
Abstract

Background Vitamin D status has been linked to diabetes-related complications due to multiple extraskeletal effects. We aimed to investigate the association between vitamin D deficiency (VDD) and diabetic vascular complications, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic foot ulcers (DFU).

Methods A total of 4284 Chinese patients with type 2 diabetic mellitus (T2DM) were enrolled into the cross-sectional study. VDD was defined as serum 25-hydroxyvitamin D < 50 nmol/L. Demographic data, physical measurements, laboratory measurements, comorbidities, and related medications were collected and analyzed by VDD status. Poisson regression with robust variance estimation and binary logistic regression were performed to explore the relationship between VDD and diabetic complications.

Results The prevalence of VDD, DR, DKD, DFU accounted to 71.7% (95% confidence intervals [CI]: 70.3%-73.0%), 28.5% (95% CI: 27.2%-29.9%), 28.2% (95% CI: 26.8%-29.5%) and 5.7% (95% CI: 5.1%-6.5%), respectively. The prevalence ratios (95% CI) for DR and DKD by VDD status, adjusted for demographics, physical measurements, laboratory measurements, related complications and comorbidities, and medications, were 1.093 (0.983–1.215) and 1.041 (0.937–1.156), respectively. The odds ratio (95% CI) for DFU by VDD status was 1.656 (1.159–2.367) in the final adjusted model. Meanwhile, the prevalence of VDD was significantly higher in patients with DFU compared with patients without DFU.

Conclusions The present study firstly indicated that VDD was significantly associated with a higher prevalence of DFU among Chinese T2DM patients. The association between VDD status and DR or DKD was not significant when adjusting for all potential covariates. Vitamin D screening or supplementation may be beneficial to prevent diabetic complications and improve the prognosis of T2DM patients.

Background

Diabetes mellitus is a severe and growing public health problem with a substantial economic burden worldwide. It is estimated that 463 million people are living with diabetes in 2019, and this estimate is projected to rise to 700 million by 2045 without urgent and sufficient actions [1]. In China, approximately 11% of the population has diabetes, with a significant proportion remaining undiagnosed [2]. More than 90% of diabetes mellitus are type 2 diabetes mellitus (T2DM). The escalating epidemic of T2DM can be attributed to ageing, the rise in obesity, sedentary lifestyles and energy-dense diets [3, 4]. T2DM can lead to severe microvascular and macrovascular complications, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic foot ulcers (DFU) [5].

Generally, DR is the main cause of preventable blindness globally, with a prevalence of approximately 34.6% [6]. The prevalence of DKD varies from 20–40% in patients with diabetes [7] and it has been the leading cause of end-stage renal disease (ESRD) in Chinese hospitalized patients since 2011 [8]. Besides, DFU is responsible for the high numbers of lower-limb amputations and increased risk of mortality of diabetic patients [9]. The prevalence of DFU is 4%-10% and the lifetime incidence has been estimated to be 10%-25% among persons with diabetes [10, 11]. All these complications lead to disability, reduce the quality of life, and impair economic development [5]. Therefore, it is of great significance to identify key modifiable factors associated with these complications so as to improve the prognosis of T2DM.

Vitamin D, a pleiotropic steroid hormone, can exert various effects through binding to its specific receptor-vitamin D receptor (VDR). In addition to mediating bone metabolism by regulating calcium and phosphorus homeostasis, vitamin D also modulates cell proliferation, differentiation, apoptosis, immune function, inflammation response, as well as vascular and metabolic properties (e.g., insulin secretion and insulin sensitivity) [12–14]. In the past few years, the association between vitamin D deficiency (VDD) and other nonclassical outcomes besides skeletal disorders has drawn increasing attention, especially diabetes and diabetes-related complications [14–17]. Although the inverse association between vitamin D levels and risk of
T2DM [18, 19], DR [20], DKD [21], or DFU [22] among diverse populations has been reported, uncertainties still exist due to the discordant results [23, 24]. More importantly, large-scale epidemiological studies on the association of VDD and diabetes-related complications among the Chinese population are scarce, especially studies evaluating the relationship between VDD and DFU.

In this cross-sectional study, we aimed to explore the prevalence of VDD, and address the associations between VDD and three severe vascular diabetic complications (i.e. DR, DKD, DFU) in a Chinese T2DM population retrospectively.

**Method**

**Study Population**

Participants we enrolled were admitted to the Department of Metabolism and Endocrinology and Diabetes Center of the Second Xiangya Hospital of Central South University from January 2014 to July 2018. Only inpatients aged ≥18 years with a definite diagnosis of type 2 diabetes were included in the study. The exclusion criteria were as follows: (1) with missing serum 25-hydroxyvitamin D (25(OH)D) data; (2) pregnant or lactating females; (3) with a known diagnosis of nephrolithiasis, glomerular or lupus nephritis, primary nephrotic syndrome, or other identified kidney diseases; (4) serum parathormone > 6.9 pmol/L or < 1.6 pmol/L; (5) serum calcium < 2.1 mmol/L or serum phosphorus < 2.1 mmol/L; (6) estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m² or missing, which was calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) equation: 186×(serum creatinine)−1.154×(age)−0.203×(0.742 if female) [25]. A total of 4284 participants were included in this cross-sectional study and their clinical data were extracted from the electronic medical record system. This study was complied with the Declaration of Helsinki and was approved by the ethics committee of the Second Xiangya Hospital of Central South University.

**Data collection**

General demographic information, including age, gender, smoking and drinking status, duration of diabetes, and family history of diabetes were collected. Physical examination (including body weight and height, blood pressure) was performed by professional caregivers. Body mass index (BMI) was calculated as weight divided by height squared and waist-hip ratio (WHR) was computed as the waist circumference divided by the hip circumference.

Fasting blood sample and 24-hour urine sample were obtained from each participant for further biochemical analysis. The laboratory measurements collected in this study included: serum 25(OH)D, albumin (ALB), triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (GLU), glycated hemoglobin (HbA1c), serum calcium (Ca), serum phosphorus (P), serum uric acid (SUA), serum creatinine (Scr) and 24-hour urine albumin (24HUALB). Notably, serum 25(OH)D concentration was determined by chemiluminescence assay (Siemens ADVIA Centaur XP, Germany) and the detection limit was < 10.5 nmol/L. When 25 (OH) D was lower than the detection limit and was treated as a continuous variable, a value of 10.5 nmol/L was used. The Homeostasis Model Assessment 2-insulin resistance (HOMA2-IR) was calculated with the HOMA2 calculator (https://www.dtu.ox.ac.uk/homacalculator/ (updated 2013).

In addition, diabetic complications (i.e., DR, DKD, DFU, diabetic peripheral neuropathy [DPN]) and related comorbidities (i.e., hypertension [HTN], dyslipidemia, coronary heart disease [CHD], cerebrovascular disease [CVD]) were also evaluated. The medication of participants included blood press-lowering therapy (BPLT) (use of angiotensin converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs]), lipid-lowering therapy (LLT) (statins) and glucose-lowering therapy (GLT). GLT was divided into four categories (i.e., no medication, oral hypoglycemic agents [OHA] only, insulin only, or using OHA plus insulin).

**Definition**
VDD was defined as serum 25(OH)D < 50 nmol/L (20 ng/mL). Conversely, the 25(OH)D level of the no VDD group was ≥ 50nmol/L. The presence of DR was confirmed by a professional ophthalmologist using dilated fundoscopy according to the definition of the Global Diabetic Retinopathy Project Group [26]. DKD was defined mainly based on albuminuria and a decline of eGFR (< 60 mL/min/1.73 m²), which was not caused by other causes than diabetes. DFU was mainly defined according to diabetic foot problems, such as ulceration, infection, ischemia, gangrene, or even amputation. DP was diagnosed by analyzing clinical symptoms, neurologic examinations and the results of nerve conduction tests. HTN was defined when blood pressure was ≥ 140/90 mmHg on three separate occasions after hospital admission by physicians, a prior diagnosis of hypertension or taking antihypertensive drugs. CHD and CVD were defined as self-reported history of CHD or CVD, respectively, regardless of disease severity. The definition of dyslipidemia was as follows: TC ≥ 6.22 mmol/L, TG ≥ 2.26 mmol/L, LDL-C ≥ 4.14 mmol/L, HDL-C < 1.04 mmol/L.

Additionally, subjects were divided into three groups by age (i.e., aged 18–44, young adults; aged 45–64, middle age adults; elderly, aged ≥ 65 years). Participants were also categorized into four groups based on the levels of BMI according to BMI criteria established by the Working Group on Obesity in China (WGOC) [27]: underweight (< 18.5 kg/m²), normal weight (18.5–23.9 kg/m²), overweight (24.0–27.9 kg/m²), and obese (≥ 28.0 kg/m²). Glycemic control was classified based on HbA1c levels as either good (< 7%) or poor (≥ 7%). The level of SUA was defined as normal (< 420 µmol/L) and high (≥ 420 µmol/L).

**Statistical analysis**

Normally distributed continuous variables were presented as the mean ± standard deviation (SD) and compared by Student’s t test. The Mann-Whitney test was used for non-normally distributed continuous variables, which were reported as median and interquartile range (25–75%). Categorical variables were summarized by frequency counts with percentages, and the chi-square test was performed to evaluate differences between groups. For continuous variables with missing values < 5%, the missing values were replaced by the mean value of the corresponding variable. Two-tailed P-values < 0.05 were considered statistically significant.

In regression analyses, a total of 4176 participants without missing value in smoking status, drinking status and family history of diabetes were included. HOMA2-IR (19.7% missing) and 24HUALB (9.0% missing) were analyzed by creating a dummy variable corresponding to missing values, respectively. As prevalence of DR and DKD in T2DM patients were not rare, Poisson regression with robust variance estimation were conducted instead of logistic regression to directly estimate the prevalence ratios (PR), along with 95% confidence intervals (CI), and to avoid the overestimation of risk ratios by odds ratio [28]. The association between VDD status and DFU was still analyzed using binary logistic regression. Potential confounders (age, gender, duration of diabetes, smoking status, drinking status, BMI and WHR) and the candidate variables with a P value < 0.1 on univariate analysis (data not shown) were all included in the multivariable model to analyze the relationship between VDD status and diabetic complications of T2DM (i.e., DR, DKD and DFU).

The SPSS software (version 25.0; IBM Corp., Armonk, NY) and Stata software (version 14.0; Stata Corp., College Station, TX) were used for statistical analysis. Graphing were performed using Graphpad Prism 7 software (Graphpad Prism Software Inc., La Jolla, CA).

## Results

### 1. Baseline characteristics of the T2DM study population

Table 1 displays the descriptive characteristics of this T2DM study population, both overall and stratified by VDD status. A total of 4284 participants were analyzed in this study. Slightly more than half (52.6%) were male and middle age adults (aged 45–64 years) made up 57.0% of the population. The proportion of participants was similar between groups with different duration of diabetes (33.5%, 34.4% and 32.1%). By our primary definition, poor glycemic control, dyslipidemia and HTN was observed in 82.1%, 64.7% and 54.0% of subjects. The proportion of patients undergoing BPLT was 41.8% and patients received LLT accounted for 73.9%. Besides, the vast majority (97.3%) were on GLT, including insulin and/or oral hypoglycemic drugs.
Table 1
Baseline characteristics among participants, overall and by VDD status

|                      | Overall | With VDD | Without VDD | P value |
|----------------------|---------|----------|-------------|---------|
| N                    | 4284    | 3071     | 1213        |         |
| **Demographics**     |         |          |             |         |
| Age, N (%)           |         |          |             |         |
| Young adults         | 539 (12.6) | 407 (13.3) | 132 (10.9) | 0.058   |
| Middle age           | 2440 (57.0) | 1721 (56.0) | 719 (59.3) |         |
| Elderly              | 1305 (30.5) | 943 (30.7) | 362 (29.8) |         |
| Gender, N (%)        |         |          |             |         |
| Male                 | 2252 (52.6) | 1528 (49.8) | 724 (59.7) | < 0.001 |
| Female               | 2032 (47.4) | 1543 (50.2) | 489 (40.3) |         |
| Smoking status, N (%)|         |          |             |         |
| Never                | 2815 (67.2) | 2033 (67.7) | 782 (65.9) | 0.053   |
| Current              | 993 (23.7) | 716 (23.9) | 277 (23.3) |         |
| Former               | 380 (9.1) | 252 (8.4) | 128 (10.8) |         |
| Drinking status, N (%)|         |          |             |         |
| Never                | 3189 (76.2) | 2324 (77.4) | 865 (72.9) | 0.001   |
| Current              | 750 (17.9) | 520 (17.3) | 230 (19.4) |         |
| Former               | 249 (6.0) | 157 (5.2) | 92 (7.8) |         |
| Family history of diabetes, N (%)| | | | |
| Yes                  | 1462 (35.0) | 1025 (34.2) | 437 (36.9) | 0.101   |
| No                   | 2717 (65.0) | 1970 (65.8) | 747 (63.1) |         |
### Duration of diabetes, N (%)

| Duration of diabetes | < 5 years | 5–10 years | > 10 years |
|----------------------|-----------|------------|------------|
|                      | 1436 (33.5) | 1037 (33.8) | 399 (32.9) |
|                      | 1475 (34.4) | 1079 (35.1) | 396 (32.7) |
|                      | 1373 (32.1) | 955 (31.1)  | 418 (34.5) |

### Physical measurements

| Physical measurement | SBP, mmHg | DBP, mmHg | BMI, N (%) |
|----------------------|-----------|-----------|------------|
|                      | 136.42 ± 19.37 | 136.95 ± 19.58 | 135.09 ± 18.76 |
|                      | 80.88 ± 11.69  | 81.07 ± 11.56  | 80.41 ± 11.99  |

### Laboratory measurements

| Laboratory measurement | ALB, g/L | Lipid profile, mmol/L |
|------------------------|---------|-----------------------|
|                        | 37.3 ± 3.9 | 37.2 ± 4.1            |
|                        | 37.5 ± 3.5 | 37.5 ± 3.5            |

| Lipid profile, mmol/L | TG | TC | LDL-C | HDL-C | GLU, mmol/L |
|-----------------------|----|----|-------|-------|-------------|
|                       | 1.60 (1.10–2.38) | 1.72 (1.18–2.58) | 1.35 (0.96–2.02) | 1.05 ± 0.29 | 7.87 (6.02–10.35) |
|                       | 1.72 (1.18–2.58) | 4.47 (3.78–5.17) | 4.19 (3.57–4.81) | 1.04 ± 0.29 | 8.08 (6.16–10.55) |
|                       | 2.68 ± 0.84 | 1.07 ± 0.28 | 7.30 (5.81–9.98) | 1.07 ± 0.28 | 7.30 (5.81–9.98) |

Table 1
|                                      | Overall       | With VDD      | Without VDD   | P value |
|--------------------------------------|---------------|---------------|---------------|---------|
| **Glycemic control, N (%)**          |               |               |               |         |
| Good                                 | 768 (17.9)    | 509 (16.6)    | 259 (21.4)    | <0.001  |
| Poor                                 | 3516 (82.1)   | 2562 (83.4)   | 954 (78.6)    |         |
| HOMA2-IR                             | 1.10 (0.76–1.65) | 1.13 (0.78–1.68) | 1.02 (0.71–1.52) | <0.001  |
| Serum Ca, mmol/L                     | 2.22 (2.16–2.30) | 2.23 (2.16–2.30) | 2.22 (2.17–2.29) | 0.547   |
| Serum P, mmol/L                      | 1.03 ± 0.18   | 1.03 ± 0.19   | 1.02 ± 0.18   | 0.068   |
| SUA status, N (%)                    |               |               |               |         |
| Normal                               | 3805 (88.8)   | 2706 (88.1)   | 1099 (90.6)   | 0.020   |
| High                                 | 479 (11.2)    | 365 (11.9)    | 114 (9.4)     |         |
| Scr, mg/dL                           | 0.71 (0.58–0.88) | 0.70 (0.57–0.87) | 0.73 (0.60–0.91) | 0.003   |
| eGFR, mL/min/1.73 m²                 | 134.38 ± 48.94 | 134.84 ± 49.24 | 133.22 ± 48.17 | 0.328   |
| 24HUALB, mg/day                      | 14.90 (6.00-61.30) | 16.17 (6.20-69.48) | 12.72 (5.60–44.00) | <0.001  |
| **Complications and comorbidities**  |               |               |               |         |
| DR, N (%)                            | 1222 (28.5)   | 908 (29.6)    | 314 (25.9)    | 0.016   |
| DKD, N (%)                           | 1207 (28.2)   | 904 (29.4)    | 303 (25.0)    | 0.003   |
| DFU, N (%)                           | 245 (5.7)     | 195 (6.4)     | 50 (4.1)      | 0.005   |
| DPN, N (%)                           | 2173 (50.7)   | 1543 (50.2)   | 630 (51.9)    | 0.318   |
| HTN, N (%)                           | 2315 (54.0)   | 1701 (55.4)   | 614 (50.6)    | 0.005   |
| Dyslipidemia, N (%)                  | 2770 (64.7)   | 2058 (67.0)   | 712 (58.7)    | <0.001  |
| CHD, N (%)                           | 823 (19.2)    | 617 (20.1)    | 206 (17.0)    | 0.020   |
| CVD, N (%)                           | 556 (13.0)    | 382 (12.4)    | 174 (14.3)    | 0.095   |
| Medication               | BPLT, N (%) | LLLT, N (%) | GLT, N (%) |
|-------------------------|-------------|-------------|------------|
| No medications         | 117 (2.7)   | 3164 (73.9) | 26 (0.6)   |
| OHA only                | 1220 (28.5) | 831 (27.1)  | 436 (10.3) |
| Insulin only            | 828 (19.3)  | 601 (19.6)  | 564 (13.6) |
| OHA plus insulin        | 2119 (49.5) | 1557 (50.7) | 1052 (27.5) |

VDD, vitamin D deficiency; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WHR, waist-hip ratio; ALB, albumin; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLU, fasting plasma glucose; HOMA2-IR, Homeostasis Model Assessment 2-insulin resistance; Ca, calcium; P, phosphorus; SUA, serum uric acid; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; 24HUALB, 24-hour urine albumin; DR, diabetic retinopathy; DKD, diabetic kidney disease; DFU, diabetic foot ulcers; DPN, diabetic peripheral neuropathy; HTN, hypertension; CHD, coronary heart disease; CVD, cerebrovascular disease; BPLT, blood pressure lowering therapy; LLT, lipid lowering therapy; GLT, glucose lowering therapy; OHA, oral hypoglycemic agents.

In bivariate analyses, compared with persons without VDD, persons with VDD were more likely to be female (50.2% vs. 40.3%, P < 0.001), never drunk (77.4% vs. 72.9%, P = 0.001), have higher SBP (P = 0.005), higher rates of obesity (17.2% vs. 10.1%, P < 0.001) and higher WHR (P < 0.001). With regard to laboratory measurements, higher TG, TC, LDL-C, GLU, HOMA2-IR, and 24HUALB were observed in the VDD group (all P < 0.001), whereas relatively lower ALB, HDL-C, and Scr were detected compared with the patients without VDD (all P < 0.05). Meanwhile, patients with VDD were more prone to have poor glycemic control (83.4% vs. 78.6%, P < 0.001) and higher level of SUA (11.9% vs. 9.4%, P = 0.02). Additionally, participants with VDD were more vulnerable to DR (29.6% vs. 25.9%, P = 0.016), DKD (29.4% vs. 25.0%, P = 0.003), DFU (6.4% vs. 4.1%, P = 0.005), HTN (55.4% vs. 50.6%, P = 0.005), dyslipidemia (67.0% vs. 58.7%, P < 0.001), and CHD (20.1% vs. 17.0%, P = 0.02), relative to those without VDD. Significant differences were also found with respect to medication between the two groups, including BPLT, LLT and GLT (all P < 0.05). Besides, Additional file 1 (Table S1) displays the prevalence of VDD and three diabetic vascular complications (i.e., DR, DKD and DFU). Overall, the prevalence of VDD accounted to 71.7% (95% confidence intervals [CI]: 70.3%-73.0%), which was defined as 25(OH)D levels less than 50 nmol/L. The prevalence of DR and DKD were very similar at 28.5% (95% CI: 27.2%-29.9%) and 28.2% (95% CI: 26.8%-29.5%), respectively. Besides, a total of 5.7% (95% CI: 5.1%-6.5%) of patients had a diagnosis of DFU in this study.

2. The association between prevalence of DR and VDD status

Figure 1 presents the PR and 95% CI for DR by VDD status. In unadjusted analyses (model 1), DR was associated with VDD status (PR: 1.147; 95% CI: 1.025–1.283). The association was retained when adjusting for age and gender (model 2). Meanwhile, a slightly larger PR was observed when adjusting for other demographics and physical measurements besides age and gender (model 3). Further adjusting for laboratory measurements other than diabetic complications, related comorbidities, and medications attenuated the risk, although the association remained significant (model 4) (PR: 1.132; 95% CI: 1.014–1.264). However, the significance diminished after adjusting for all variables in the final adjusted model (model 5) (PR: 1.093; 95% CI: 0.983–1.215). The final adjusted model is displayed in detail in Additional file 1 (Table S2).
3. The association between prevalence of DKD and VDD status

Models 1-5 in Fig. 2 present the Poisson regression with robust variance models for the assessment of the correlation between VDD status and the prevalence of DKD. The prevalence of DKD was significantly higher in the VDD group in comparison to no-VDD persons in the crude analysis (model 1) (PR: 1.172; 95% CI: 1.047–1.313). The associations remained markedly significant when adjusting for age and gender only (model 2) (PR: 1.202; 95% CI: 1.073–1.345) or additionally adjusting other demographics and physical measurements (model 3) (PR: 1.190; 95% CI: 1.065–1.329). However, when other possible explanatory variables associated with DKD in univariate analysis were considered, including laboratory factors, diabetic complications, related comorbidities and medications, no significant association between the VDD status and prevalence of DR was demonstrated (model 4–5). Model 5 adjusting for all variables is displayed in detail in Additional file 1 (Table S3).

4. The association between DFU and VDD status

As the prevalence of DFU was not common (5.7%) in the study population, we next performed logistic regression analyses to assess the relationship between VDD status and the prevalence of DFU (Fig. 3). In the crude model (model 1), the presence of VDD was associated with an increased prevalence of DFU (odds ratio [OR]: 1.623; 95% CI: 1.174–2.243). The association was slightly enhanced when adjusting age and gender (model 2) (OR: 1.696; 95% CI: 1.223–2.350). Besides, an obvious increase in the odds of DFU was observed after additional adjustment of other demographics and physical measurements (i.e. duration of diabetes, smoking status, drinking status, family history of diabetes, BMI and WHR) (model 3) (OR: 1.840; 95% CI: 1.322–2.561). When further controlling for the biochemical indices (i.e., ALB, TG, TC, HDL-C, LDL-C, serum Ca, Scr and 24HUALB) (model 4), participants with VDD still had a greater prevalence of DFU compared with the no-VDD group. Final adjustment for diabetic complications, related comorbidities and medications, attenuated the association between VDD status and DFU, but did not remove statistical significance (model 5) (OR: 1.656; 95% CI: 1.159–2.367). Additional file 1 (Table S4) displays all variables included in the final adjusted model.

5. Vitamin D metrics by DFU status, overall and by gender

We also evaluated the proportions of VDD and 25(OH) levels between the DFU group and the no-DFU group (Table 2). Overall, compared with subjects without DFU, persons with DFU had higher prevalence of VDD (79.59% vs. 71.21%, P = 0.005) and lower serum 25(OH)D levels (36.96 ± 18.03 nmol/L vs. 40.97 ± 17.82 nmol/L, P = 0.001). When stratified by gender, similar results were observed in men (all P < 0.05), while there were no significant differences in the prevalence of VDD between these two groups in women (83.02% vs. 75.55%, P = 0.08). Moreover, in the DFU group, it seemed that the 25(OH)D levels in men were slightly greater than that in women, although it did not reach statistical significance (38.86 ± 19.26 nmol/L vs. 34.46 ± 16.03 nmol/L, P = 0.058).
|                               | DFU                   | No DFU              | P value |
|-------------------------------|-----------------------|---------------------|---------|
| **Overall**                   |                       |                     |         |
| N                             | 245                   | 4039                |         |
| VDD, N (%)                    | 195 (79.59)           | 2876 (71.21)        | 0.005   |
| 25(OH)D, nmol/L               | 36.96 ± 18.03         | 40.97 ± 17.82       | 0.001   |
| **Male**                      |                       |                     |         |
| N                             | 139                   | 2113                |         |
| VDD, N (%)                    | 107 (76.98)           | 1421 (67.25)        | 0.017   |
| 25(OH)D, nmol/L               | 38.86 ± 19.26         | 42.87 ± 18.04       | 0.012   |
| **Female**                    |                       |                     |         |
| N                             | 106                   | 1926                |         |
| VDD, N (%)                    | 88 (83.02)            | 1455 (75.55)        | 0.080   |
| 25(OH)D, nmol/L               | 34.46 ± 16.03         | 38.89 ± 17.36       | 0.010   |

VDD, vitamin D deficiency; DFU, diabetic foot ulcer; 25(OH)D, 25-hydroxyvitamin D.

**Discussion**

In this study, approximately 71.7% of Chinese hospitalized patients with T2DM developed VDD. Patients with VDD had higher prevalence of DFU after adjustment for demographics, physical measurements, laboratory indices, related treatment factors and comorbidities compared with patients without VDD, whereas the associations between VDD status and another two microvascular complications (i.e., DR and DKD) were not statistically significant.

VDD is a growing epidemic condition around the world [29], the prevalence of which varies by race, latitudes, and seasons [20]. An estimated 50%-80% of the general population is affected by vitamin D insufficiency or VDD globally [30]. In northwest and north China, the prevalence of VDD was about 75.2% and 87.1%, respectively [31, 32]. VDD is also quite common among Chinese patients with T2DM. A Chinese cross-sectional survey among diabetic inpatients reported that the proportions of persons with VDD were 83.5%, the recruitment center of which was located in north China (latitude 34°-37° N) [33]. Besides, approximately 62.7% of T2DM subjects were affected in two epidemiological studies conducted in Nanjing, which is located in eastern coastal China (latitude 31°-33° N) [21]. In present study, we found that the prevalence of VDD was about 71.7% among this study...
population with T2DM, who were recruited in Changsha, a city located in central China (latitude 27°-29° N). Although the discordance in prevalence of VDD could partially explained by latitude, other factors such as diet and lifestyle must be considered.

Furthermore, we found that the prevalence of DR and DKD in this study population was 28.5% and 28.2%, respectively. The results were roughly in line with previous studies [34, 35]. However, the proportion of DFU (5.7%, 95% CI: 5.1%-6.5%) was much lower in comparison to a previous study conducted in Wuhan, China (11.4%) [36], although it was much higher than the prevalence reported in 2010 (0.8%) by a cross-sectional study conducted in Shanghai, China [37]. We believed that the actual prevalence of DFU may be underestimated. One plausible interpretation was the presence of missed diagnosis of DFU during admission. Some patients without acute symptoms (e.g., ulceration, infection, swollen foot with pain) may not receive further examinations due to socioeconomic concerns. Besides, DFU is generally considered as the consequences of diabetic neuropathy and/or peripheral arterial disease (PAD) [7]. Sometimes patients with PAD may remain undiagnosed until severe tissue loss appears, which also add to the difficulty of the correct diagnosis of DFU [38]. We also addressed that in rural areas of China, a higher proportion of DFU remains undiagnosed because of the less medical access and limited knowledge on this severe diabetic complication. Therefore, future efforts should be directed at early diagnosis of DFU in both urban and rural areas.

DR is the leading cause of visual impairments among working-aged adults suffered from diabetes [39]. The risk factors contributed to the progression of DR include poor glycemic control, long duration of diabetes, inflammation, obesity, and hypertension [20]. Vitamin D status is hypothesized to prevent DR mainly due to its inhibitory effects on inflammation and angiogenesis [40, 41]. Lu et al. [42] also demonstrated that vitamin D could decrease diabetes-induced reactive oxygen species and exert protective effects against retinal vascular damage and cell apoptosis. Many clinical studies have recognized VDD as a risk factor for DR [16, 43-45], whereas other epidemiological researches showed an opposite result [19, 23, 46, 47]. In this study, we took full advantage of the data already gathered and we reported that VDD status was associated with a higher prevalence of DR when adjusting demographics, physical measurements and biochemical indices (PR: 1.132; 95% CI: 1.014–1.264). However, further adjustments of comorbidities, diabetic complications and medication use attenuated the association and removed the statistical significance. These discrepancies may be result from variations in population sampling, the diagnosis of DR and the covariates included in the regression analyses. Considering all the published data, the connection between vitamin D levels and risk of DR remains inconclusive in Chinese population and further studies are required.

DKD is one of the most common microvascular complications of diabetes, the histology of which is characterized by glomerular basement membrane (GBM) thickening, mesangial matrix expansion, nodular glomerulosclerosis, and arteriolar hyalinosis [48]. Many researches have explored the mechanisms underlying the renoprotective effects of vitamin D. The effects of vitamin D are mediated by VDR, which is widely expressed in various renal cells, such as glomerular mesangial cells, podocytes and tubular cells [49-51]. VDR down-regulation is associated with the severity of albuminuria in T2DM patients [52]. Accumulating evidence suggested that vitamin D may protect the kidney through alleviating oxidative stress [53], reducing inflammation response by blunting nuclear factor-kappa B (NF-kB) activation [54], preventing epithelial-to-mesenchymal transformation, and suppressing the expression of transforming growth factor-β [49, 55]. Moreover, vitamin D also can inhibit the renin-angiotensin-aldosterone system (RAAS) through down-regulating renin expression, which plays a crucial role in the pathogenesis of DKD [56, 57]. However, clinical studies pertaining to the association between vitamin D status and DKD have reported inconsistent results. A recent cross-sectional study of 351 Chinese inpatients with T2DM demonstrated that VDD was independently associated with DKD [21]. This was consistent with many previous studies which had linked albuminuria to low vitamin D levels [58-62]. Conversely, several studies reported discordant results [24, 63, 64]. In this study, we revealed that the correlation between VDD status and prevalence of DKD was not statistically significant after adjusting laboratory measurements, diabetic complications, related comorbidities and medications besides the adjustment for demographics and physical measurements. These conflict results may be mainly due to differences in study population and adjusted covariates. Besides, the evidence for vitamin D supplementation to prevent DKD remains weak due to the discordances in published data [65-68]. Taken together, the impacts of VDD on DKD need to be further studied in the future.
Conclusion
VDD is a very common condition among Chinese T2DM patients. Decreased vitamin D levels were associated with a higher prevalence of diabetes-related complications, especially DFU. The association between VDD status and DFU was significant and independent of numerous potential confounders, including demographics, physical measurements, biochemical indices, related comorbidities and complications, as well as medication use. Vitamin D supplementation by dietary or other intervention strategies to correct VDD in Chinese diabetic population may help prevent the development of diabetic complications.

**Abbreviations**

T2DM: type 2 diabetes mellitus; DR: diabetic retinopathy; DKD: diabetic kidney disease; DFU: diabetic foot ulcers; ESRD: end-stage renal disease; VDR: vitamin D receptor; VDD: vitamin D deficiency; 25(OH)D: 25-hydroxyvitamin D; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist-hip ratio; ALB: albumin; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; GLU: fasting plasma glucose; HbA1c: glycated hemoglobin; HOMA2-IR: Homeostasis Model Assessment 2-insulin resistance; Ca: calcium; P: phosphorus; SUA: serum uric acid; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; 24HUALB: 24-hour urine albumin; DPN: diabetic peripheral neuropathy; HTN: hypertension; CHD: coronary heart disease; CVD: cerebrovascular disease; BPLT: blood pressure lowering therapy; ACEIs: angiotensin converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; LLT: lipid lowering therapy; GLT: glucose lowering therapy; OHA: oral hypoglycemic agents; PAD: peripheral arterial disease; NF-κB: nuclear factor-kappa B; RAAS: renin-angiotensin-aldosterone system; SD: standard deviation; PR: prevalence ratios; OR: odds ratio; CI: confidence intervals.

**Declarations**

**Acknowledgements**

The authors thank all team members and participants of this study.

**Author Contributions**

Ying Xiao designed the study, analyzed the data, interpreted the results, and drafted the manuscript. Ying Xiao, Ling Wei and Xiaofen Xiong contributed to data collection and manuscript revision. Ming Yang provided support for interpreting the results and revising the manuscript. Lin Sun is the corresponding author and was involved in the study design, data interpretation and manuscript revision. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from the National Key R&D Program of China (2018YFC1314002) and the Key Program of General Program of the National Natural Science Foundation of China (NSFC) (81730018). The founders did not involve in study design, data collection, analysis, interpretation, and decision to prepare or submit this article for publication.
Availability of data and materials

The datasets used and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The cross-sectional study was approved by the ethics committee of the Second Xiangya Hospital of Central South University. Formal informed consent is not required. Our institutional board deems the study exempt. The study protocol was in accordance with the guidelines of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest

References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.
2. Ma RCW. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 2018;61(6):1249-60.
3. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.
4. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239-51.
5. Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017;356:i6505.
6. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-64.
7. American Diabetes A. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S135-S51.
8. Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, et al. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016;375(9):905-6.
9. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367-75.
10. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-28.
11. Armstrong DG, Hanft JR, Driver VR, Smith AP, Lazaro-Martinez JL, Reyzelman AM, et al. Effect of oral nutritional supplementation on wound healing in diabetic foot ulcers: a prospective randomized controlled trial. Diabet Med. 2014;31(9):1069-77.
12. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr Rev. 2019;40(4):1109-51.
13. Sintov AC, Yarmolinsky L, Dahan A, Ben-Shabat S. Pharmacological effects of vitamin D and its analogs: recent developments. Drug Discov Today. 2014;19(11):1769-74.
14. Grammatiki M, Rapti E, Karras S, Ajran RA, Kotsa K. Vitamin D and diabetes mellitus: Causal or casual association? Rev Endocr Metab Disord. 2017;18(2):227-41.

15. Zoppini G, Galletti A, Targher G, Brangani C, Pichiri I, Trombetta M, et al. Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3(1):e000058.

16. Herrmann M, Sullivan DR, Veillard AS, McCorquodale T, Straub IR, Scott R, et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care. 2015;38(3):521-8.

17. Yammine K, Hayek F, Assi C. Is there an association between vitamin D and diabetic foot disease? A meta-analysis. Wound Repair Regen. 2020;28(1):90-6.

18. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013;36(5):1422-8.

19. Reddy GB, Sivaprasad M, Shalini T, Satyanarayana A, Seshacharyulu M, Balakrishna N, et al. Plasma vitamin D status in patients with type 2 diabetes with and without retinopathy. Nutrition. 2015;31(7-8):959-63.

20. Luo BA, Gao F, Qin LL. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017;9(3).

21. Xie S, Huang L, Cao W, Hu Y, Sun H, Cao L, et al. Association between serum 25-hydroxyvitamin D and diabetic kidney disease in Chinese patients with type 2 diabetes. PLoS One. 2019;14(4):e0214728.

22. Pena G, Kuang B, Cowled P, Howell S, Dawson J, Philpot R, et al. Micronutrient Status in Diabetic Patients with Foot Ulcers. Adv Wound Care (New Rochelle). 2020;9(1):9-15.

23. Alam U, Amjad Y, Chan AW, Asghar O, Petropoulos IN, Malik RA. Vitamin D Deficiency Is Not Associated with Diabetic Retinopathy or Maculopathy. J Diabetes Res. 2016;2016:6156217.

24. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care. 2010;33(10):2238-43.

25. He WY, Bai Q, A LT, Tang CS, Zhang AH. Irisin levels are associated with urotensin II levels in diabetic patients. J Diabetes Investig. 2015;6(5):571-6.

26. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-82.

27. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83-96.

28. Knol MJ, Le Cessie S, Algra A, Vandebroucke JP, Groenwold RH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. CMAJ. 2012;184(8):895-9.

29. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720-55.

30. van Schoor N, Lips P. Global Overview of Vitamin D Status. Endocrinol Metab Clin North Am. 2017;46(4):845-70.

31. Zhen D, Liu L, Guan C, Zhao N, Tang X. High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors. Bone. 2015;71:1-6.

32. Ning Z, Song S, Miao L, Zhang P, Wang X, Liu J, et al. High prevalence of vitamin D deficiency in urban health checkup population. Clin Nutr. 2016;35(4):859-63.

33. Peng Y, Li LJ. Serum 25-hydroxyvitamin D level and diabetic nephropathy in patients with type 2 diabetes mellitus. Int Urol Nephrol. 2015;47(6):983-9.

34. Zhang G, Chen H, Chen W, Zhang M. Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study. Br J Ophthalmol. 2017;101(12):1591-5.

35. Mok KY, Chan PF, Lai LKP, Chow KL, Chao DVK. Prevalence of diabetic nephropathy among Chinese patients with type 2 diabetes mellitus and different categories of their estimated glomerular filtration rate based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in primary care in Hong Kong: a cross-sectional study. J Diabetes Metab Disord. 2019;18(2):281-8.

36. Zhong A, Li G, Wang D, Sun Y, Zou X, Li B. The risks and external effects of diabetic foot ulcer on diabetic
patients: A hospital-based survey in Wuhan area, China. Wound Repair Regen. 2017;25(5):858-63.

37. Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8:62.

38. Hinchliffe RJ, Forsythe RO, Apelqvist J, Boyko EJ, Fitridge R, Hong JP, et al. Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36 Suppl 1:e3276.

39. Song P, Yu J, Chan KY, Theodoratou E, Rudan I. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health. 2018;8(1):010803.

40. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008;294(5):F1059-64.

41. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmd Vis Sci. 1995;36(1):83-7.

42. Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway. J Diabetes Res. 2018;2018:8193523.

43. Alcubierre N, Valls J, Rubinat E, Cao G, Esquerda A, Traveset A, et al. Vitamin D Deficiency Is Associated with the Presence and Severity of Diabetic Retinopathy in Type 2 Diabetes Mellitus. J Diabetes Res. 2015;2015:374178.

44. He R, Shen J, Liu F, Zeng H, Li L, Yu H, et al. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med. 2014;31(12):1657-64.

45. Ashinne B, Rajalakshmi R, Anjana RM, Narayan KMV, Jayashri R, Mohan V, et al. Association of serum vitamin D levels and diabetic retinopathy in Asian Indians with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:308-13.

46. Bonakdarzan S, Shoeibi N. Is there any correlation between vitamin D insufficiency and diabetic retinopathy? Int J Ophthalmol. 2015;8(2):326-31.

47. Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ, Group VS. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis. 2013;228(2):502-7.

48. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361-77.

49. Plum LA, Zella JB. Vitamin D compounds and diabetic nephropathy. Arch Biochem Biophys. 2012;523(1):87-94.

50. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73(2):163-71.

51. Yang S, Li A, Wang J, Liu J, Han Y, Zhang W, et al. Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases. Curr Med Chem. 2018;25(27):3256-71.

52. Yi B, Huang J, Zhang W, Li AM, Yang SK, Sun J, et al. Vitamin D Receptor Down-Regulation Is Associated With Severity of Albuminuria in Type 2 Diabetes Patients. J Clin Endocrinol Metab. 2016;101(11):4395-404.

53. Deng X, Cheng J, Shen M. Vitamin D improves diabetic nephropathy in rats by inhibiting renin and relieving oxidative stress. J Endocrinol Invest. 2016;39(6):657-66.

54. Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, et al. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007;72(2):193-201.

55. Li YC. Podocytes as target of vitamin D. Curr Diabetes Rev. 2011;7(1):35-40.

56. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, et al. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282(41):29821-30.

57. Hu X, Liu W, Yan Y, Liu H, Huang Q, Xiao Y, et al. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism. Eur J Pharmacol. 2019;845:91-8.

58. Fernandez-Juarez G, Luno J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013;8(11):1870-6.

59. Xiao X, Wang Y, Hou Y, Han F, Ren J, Hu Z. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016;44(3):673-84.
60. Damasiewicz MJ, Magliano DJ, Daly RM, Gagnon C, Lu ZX, Sikaris KA, et al. Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am J Kidney Dis. 2013;62(1):58-66.

61. Ucak S, Sevim E, Ersoy D, Sivritepe R, Basat O, Atay S. Evaluation of the relationship between microalbuminuria and 25-(OH) vitamin D levels in patients with type 2 diabetes mellitus. Aging Male. 2019;22(2):116-20.

62. Skaaby T, Husemoen LL, Pisinger C, Jorgensen T, Thuesen BH, Rasmussen K, et al. Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. Endocrine. 2013;44(2):473-80.

63. Guessous I, McClellan W, Kleinbaum D, Vaccarino V, Hugues H, Boulat O, et al. Serum 25-hydroxyvitamin D level and kidney function decline in a Swiss general adult population. Clin J Am Soc Nephrol. 2015;10(7):1162-9.

64. Urena-Torres P, Metzger M, Haymann JP, Karras A, Boffa JJ, Flamant M, et al. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis. 2013;58(4):544-53.

65. Ahmadi N, Mortazavi M, Iraj B, Askari G. Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? J Res Med Sci. 2013;18(5):374-7.

66. Taheiri S, Asim M, Al Malki H, Fituri O, Suthanthiran M, August P, et al. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial. Trials. 2018;19(1):230.

67. Wang S, Yin C, Han X, Guo A, Chen X, Liu S, et al. Improved Healing of Diabetic Foot Ulcer upon Oxygenation Therapeutics through Oxygen-Loading Nanoperfluorocarbon Triggered by Radial Extracorporeal Shock Wave. Oxid Med Cell Longev. 2019;2019:5738368.

68. Trujillo V, Marin-Luevano P, Gonzalez-Curiel I, Rodriguez-Carlos A, Ramirez-Reyes M, Layseca-Espinosa E, et al. Calcitriol promotes proangiogenic molecules in keratinocytes in a diabetic foot ulcer model. J Steroid Biochem Mol Biol. 2017;174:303-11.

69. Yuan YF, Das SK, Li MQ. Vitamin D Ameliorates Impaired Wound Healing in Streptozotocin-Induced Diabetic Mice by Suppressing Endoplasmic Reticulum Stress. J Diabetes Res. 2018;2018:1757925.

70. Vanherwegen AS, Gysemans C, Mathieu C. Vitamin D endocrinology on the cross-road between immunity and metabolism. Mol Cell Endocrinol. 2017;453:52-67.

71. Mayer O, Seidlerova J, Cerna V, Kucerova A, Hronova M, et al. Serum Vitamin D Status, Vitamin D Receptor Polymorphism, and Glucose Homeostasis in Healthy Subjects. Horm Metab Res. 2018;50(1):56-64.

72. Oda Y, Hu L, Nguyen T, Fong C, Zhang J, Guo P, et al. Vitamin D Receptor Is Required for Proliferation, Migration, and Differentiation of Epidermal Stem Cells and Progeny during Cutaneous Wound Repair. J Invest Dermatol. 2018;138(11):2423-31.

73. Feldkamp J, Jungheim K, Schott M, Jacobs B, Roden M. Severe Vitamin D3 Deficiency in the Majority of Patients with Diabetic Foot Ulcers. Horm Metab Res. 2018;50(8):615-9.

74. Tiwari S, Pratyush DD, Gupta SK, Singh SK. Vitamin D deficiency is associated with inflammatory
cytokine concentrations in patients with diabetic foot infection. Br J Nutr. 2014;112(12):1938-43.

82. Dai J, Jiang C, Chen H, Chai Y. Vitamin D and diabetic foot ulcer: a systematic review and meta-analysis. Nutr Diabetes. 2019;9(1):8.

### Figures

**Figure 1**
Prevalence ratios of DR by VDD status among the study population. Model 1: crude, unadjusted; model 2: adjusted for age, gender; model 3: adjusted for age, gender, duration of diabetes, smoking status, drinking status, BMI and WHR; model 4: model 3 + ALB, TG, HDL-C, glycemic control, HOMA2-IR, serum Ca, serum P, SUA, Scr, 24HUALB; model 5: model 4 + diabetic complications (DKD, DFU, DPN), related comorbidities (CHD, CVD and HTN), and medications (BPLT, LLT and GLT).

| Model   | PR of DR (95%CI) |
|---------|------------------|
| Model 1 | 1.147 (1.025-1.283) |
| Model 2 | 1.128 (1.009-1.262) |
| Model 3 | 1.167 (1.046-1.302) |
| Model 4 | 1.132 (1.014-1.264) |
| Model 5 | 1.093 (0.983-1.215) |
| Model     | PR of DKD (95% CI)          | P value |
|-----------|----------------------------|---------|
| Model 1   | 1.172 (1.047-1.313)         | 0.0     |
| Model 2   | 1.202 (1.073-1.345)         | 0.0     |
| Model 3   | 1.190 (1.065-1.329)         | 0.0     |
| Model 4   | 1.079 (0.968-1.202)         | 0.1     |
| Model 5   | 1.041 (0.937-1.156)         | 0.4     |

Figure 2
Prevalence ratios of DKD by VDD status among the study population. Model 1: crude, unadjusted; model 2: adjusted for age, gender; model 3: adjusted for age, gender, duration of diabetes, smoking status, drinking status, BMI and WHR; model 4: model 3 + ALB, TC, LDL-C, glycemic control, HOMA2-IR, serum Ca, serum P, SUA, Scr, 24HUALB; model 5: model 4 + diabetic complications (DR, DFU, DPN), related comorbidities (CHD, CVD and HTN), and medications (BPLT, LLT and GLT).
| Model     | OR of DFU (95%CI)               | P value |
|-----------|---------------------------------|---------|
| Model 1   | 1.623 (1.174-2.243)             | 0.1     |
| Model 2   | 1.696 (1.223-2.350)             | 0.1     |
| Model 3   | 1.840 (1.322-2.561)             | <0      |
| Model 4   | 1.770 (1.256-2.495)             | 0.1     |
| Model 5   | 1.656 (1.159-2.367)             | 0.1     |

Figure 3

Odds ratio of DFU by VDD status among the study population. Model 1: crude, unadjusted; model 2: adjusted for age, gender; model 3: adjusted for age, gender, duration of diabetes, smoking status, drinking status, family history of diabetes, BMI and WHR; model 4: model 3 + ALB, TG, TC, HDL-C, LDL-C, serum Ca, Scr, 24HUALB; model 5: model 4 + diabetic complications (DR, DKD, DPN), related comorbidities (CHD, CVD and HTN), and medications (BPLT, LLT and GLT).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx